Reuters logo
BRIEF-Beigene announces dosing of first patient in a pivotal clinical trial of BGB-3111
March 2, 2017 / 2:18 PM / 7 months ago

BRIEF-Beigene announces dosing of first patient in a pivotal clinical trial of BGB-3111

March 2 (Reuters) - Beigene Ltd

* Beigene Ltd - dosing of first patient in a pivotal clinical trial of BGB-3111

* Beigene - BGB-3111 is evaluated in global Phase III study in comparison with ibrutinib for treatment of patients with Waldenström’s macroglobulinemia Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below